Cargando…
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
Metastatic renal cell carcinoma (mRCC) treatments have rapidly evolved in the last few years. While vascular endothelial growth factor (VEGF) inhibition had previously been the mainstay of treatment for first-line advanced RCC therapy in the past decade, it has now rapidly changed into combination c...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045961/ https://www.ncbi.nlm.nih.gov/pubmed/33884285 http://dx.doi.org/10.18632/oncoscience.528 |
_version_ | 1783678759637876736 |
---|---|
author | Aragon-Ching, Jeanny B. |
author_facet | Aragon-Ching, Jeanny B. |
author_sort | Aragon-Ching, Jeanny B. |
collection | PubMed |
description | Metastatic renal cell carcinoma (mRCC) treatments have rapidly evolved in the last few years. While vascular endothelial growth factor (VEGF) inhibition had previously been the mainstay of treatment for first-line advanced RCC therapy in the past decade, it has now rapidly changed into combination checkpoint inhibitors with or without VEGF TKIs, although there remains a role for VEGF tyrosine kinase inhibitor monotherapy for patients with favorable-risk disease and for those with intermediate and poor-risk disease with the use of cabozantinib. Perspectives on the Quality-adjusted survival Time without Symptoms of disease or Toxicity (Q-TWiST) analysis for the CABOSUN trial, as well as different aspects of efficacy regarding different first-line therapy for advanced or metastatic RCC are discussed herein. |
format | Online Article Text |
id | pubmed-8045961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-80459612021-04-20 Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies Aragon-Ching, Jeanny B. Oncoscience Research Perspective Metastatic renal cell carcinoma (mRCC) treatments have rapidly evolved in the last few years. While vascular endothelial growth factor (VEGF) inhibition had previously been the mainstay of treatment for first-line advanced RCC therapy in the past decade, it has now rapidly changed into combination checkpoint inhibitors with or without VEGF TKIs, although there remains a role for VEGF tyrosine kinase inhibitor monotherapy for patients with favorable-risk disease and for those with intermediate and poor-risk disease with the use of cabozantinib. Perspectives on the Quality-adjusted survival Time without Symptoms of disease or Toxicity (Q-TWiST) analysis for the CABOSUN trial, as well as different aspects of efficacy regarding different first-line therapy for advanced or metastatic RCC are discussed herein. Impact Journals LLC 2021-03-21 /pmc/articles/PMC8045961/ /pubmed/33884285 http://dx.doi.org/10.18632/oncoscience.528 Text en Copyright: © 2021 Aragon-Ching. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Perspective Aragon-Ching, Jeanny B. Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies |
title |
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
|
title_full |
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
|
title_fullStr |
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
|
title_full_unstemmed |
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
|
title_short |
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
|
title_sort | balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (rcc) studies |
topic | Research Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045961/ https://www.ncbi.nlm.nih.gov/pubmed/33884285 http://dx.doi.org/10.18632/oncoscience.528 |
work_keys_str_mv | AT aragonchingjeannyb balancingefficacyandqualityoflifemeasurementsamongmetastaticrenalcellcarcinomarccstudies |